During the past decade, Hemophilia Center of Western Pennsylvania conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 9 clinical trials were completed, i.e. on average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hemophilia Center of Western Pennsylvania" #1 sponsor was "Margaret Ragni" with 6 trials, followed by "Baxalta now part of Shire" with 4 trials sponsored, "Spark Therapeutics" with 4 trials sponsored, "American Thrombosis and Hemostasis Network" with 3 trials sponsored and "Avigen" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hemophilia Center of Western Pennsylvania" #1 collaborator was "Children's Hospital of Philadelphia" with 3 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Health Resources and Services Administration (HRSA)" with 2 trials as a collaborator and "Hemophilia of Georgia, Inc." with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Hemophilia Center of Western Pennsylvania" are "Hemophilia A" (10 trials), "Hemophilia B" (4 trials), "Von Willebrand Disease" (4 trials), "Hemophilia" (3 trials) and "Von Willebrand Diseases" (3 trials). Many other conditions were trialed in "Hemophilia Center of Western Pennsylvania" in a lesser frequency.

Most popular intervention types in "Hemophilia Center of Western Pennsylvania" are "Drug" (17 trials), "Biological" (6 trials), "Genetic" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Antihemophilic factor, recombinant, manufactured protein-free" (2 trials), "Eloctate ITI" (2 trials), "SPK-8011" (2 trials), "Adeno-Associated Viral with Human Factor IX" (1 trials) and "Advate (High Dose)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hemophilia Center of Western Pennsylvania" are 17 trials for "Male" genders, 11 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hemophilia Center of Western Pennsylvania". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in Hemophilia Center of Western Pennsylvania, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Hemophilia Center of Western Pennsylvania, 7 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".